Last Updated : October 24, 2019
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC1203-000
Question
- What is the clinical effectiveness of intravenous ketamine for adults with treatment-resistant depression or post-traumatic stress disorder?
- What is cost-effectiveness of intravenous ketamine for adults with treatment-resistant depression or post-traumatic stress disorder?
- What are the evidence-based guidelines regarding the use and administration of intravenous ketamine for adults with treatment-resistant depression or post-traumatic stress disorder?
Key Message
Three randomized controlled trials reported that intravenous ketamine was significantly more effective than placebo or midazolam for the treatment of adults with treatment-resistant depression. One randomized controlled trial reported no significant difference between intravenous ketamine (six repeated doses of 0.5mg/kg) and placebo. One evidence-based guideline reported a strong recommendation against treating post-traumatic stress disorder with ketamine monotherapy. No relevant evidence regarding the clinical effectiveness of intravenous ketamine for the treatment of post-traumatic stress disorder or the cost-effectiveness of intravenous ketamine for treatment-resistant depression or post-traumatic stress disorder was identified.
Files
Last Updated : October 24, 2019